Umpqua Bank Sells 508 Shares of Kenvue Inc. (NYSE:KVUE)

Umpqua Bank reduced its holdings in Kenvue Inc. (NYSE:KVUE) by 4.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 12,286 shares of the company’s stock after selling 508 shares during the quarter. Umpqua Bank’s holdings in Kenvue were worth $223,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Ceera Investments LLC acquired a new stake in Kenvue in the 2nd quarter valued at approximately $1,048,000. Isthmus Partners LLC grew its stake in shares of Kenvue by 1.2% in the second quarter. Isthmus Partners LLC now owns 535,540 shares of the company’s stock worth $97,000 after acquiring an additional 6,274 shares during the last quarter. Cullen Frost Bankers Inc. increased its position in Kenvue by 17.8% during the second quarter. Cullen Frost Bankers Inc. now owns 307,224 shares of the company’s stock worth $5,585,000 after acquiring an additional 46,377 shares during the period. Gentry Private Wealth LLC acquired a new position in Kenvue during the 2nd quarter valued at $362,000. Finally, Boyar Asset Management Inc. boosted its holdings in Kenvue by 16.5% in the 2nd quarter. Boyar Asset Management Inc. now owns 27,223 shares of the company’s stock valued at $495,000 after purchasing an additional 3,856 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $22.86 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The business’s fifty day moving average price is $19.92 and its two-hundred day moving average price is $19.67. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.00. The stock has a market capitalization of $43.77 billion, a price-to-earnings ratio of 29.31, a price-to-earnings-growth ratio of 2.76 and a beta of 1.40.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same quarter in the prior year, the firm earned $0.32 EPS. The firm’s quarterly revenue was down .3% compared to the same quarter last year. As a group, analysts predict that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were issued a dividend of $0.205 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.59%. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. UBS Group upped their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of Kenvue in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their target price on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, Citigroup decreased their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average price target of $21.44.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.